In the news
In the news, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.179 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 14, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.175NatureArticleSnippet(type=short-summary, markup=The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those with RET mutations, or RET-rearranged lung cancers. Herein, the authors outline the aberrations in RET that contribute to tumorigenesis, review the curr...
Source: Nature Clinical Practice Oncology - November 14, 2017 Category: Cancer & Oncology Authors: Alexander Drilon Zishuo I. Hu Gillianne G. Y. Lai Daniel S. W. Tan Source Type: research
Immunotherapy: Nice to see you — evolving MHC I–peptide presentation
Immunotherapy: Nice to see you — evolving MHC I–peptide presentation, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.180 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 14, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Tumour heterogeneity and resistance to cancer therapies
Tumour heterogeneity and resistance to cancer therapies, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.166NatureArticleSnippet(type=short-summary, markup=The onset of acquired resistance to treatment is virtually inevitable in patients with solid tumours. In this Review, the authors describe the role of tumour heterogeneity in the development of acquired resistance, potential treatment strategies that take into account the heterogeneity of patient's tumours, and how a better understanding of tumour heterogeneity might improve the outcomes of patients., isJats=true) (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 8, 2017 Category: Cancer & Oncology Authors: Ibiayi Dagogo-Jack Alice T. Shaw Source Type: research
Drug development for noncastrate prostate cancer in a changed therapeutic landscape
Drug development for noncastrate prostate cancer in a changed therapeutic landscape, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.177 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 8, 2017 Category: Cancer & Oncology Authors: Min Yuen Teo Matthew J. O ' Shaughnessy Sean M. McBride Herbert A. Vargas Howard I. Scher Source Type: research
Immunotherapy: Nivolumab-induced alterations revealed
Immunotherapy: Nivolumab-induced alterations revealed, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.173 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 8, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Immunotherapy: Gain beyond injection
Nature Reviews Clinical Oncology, Published online: 25 October 2017; doi:10.1038/nrclinonc.2017.172 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 25, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Skin cancer: Propranolol limits melanoma recurrence
Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.170 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 17, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
Drug development for noncastrate prostate cancer in a changed therapeutic landscape
Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.160Clinical trials are an essential aspect of drug development; however, in patients with non-castrate prostate cancer, the long natural history of the disease provides a major barrier to the introduction of new therapies. In this Review, the authors describe the potential of a novel, multi-arm, multistage, clinical trial project, with surrogate end points designed to fully reflect the effects of treatments, in transforming the treatment of patients with early stage prostate cancer, before the development of castration-resistant...
Source: Nature Clinical Practice Oncology - October 17, 2017 Category: Cancer & Oncology Authors: Min Yuen Teo Matthew J. O ' Shaughnessy Sean M. McBride Herbert A. Vargas Howard I. Scher Source Type: research
Breast Cancer: Abemaciclib effective in combination with aromatase inhibition
Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.169 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 17, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Imaging biomarkers exist and they underpin clinical decision-making
Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.167 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 17, 2017 Category: Cancer & Oncology Authors: John C. Waterton Lisa M. McShane James P. B. O ' Connor Source Type: research
Haematological cancer: Extended EFS with rituximab
Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.168 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 17, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Breast cancer: LAG3 expression indicates favourable outcomes
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.164 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Lung Cancer: Dacomitinib delays disease progression
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.162 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Lung Cancer: SABR effective against oligometastatic disease
Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.165 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
